Back to search
FDAFDA · Food and drugs·Recall number D-0559-2024

Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03

Published June 26, 2024 · Recall initiated: May 30, 2024

Summary

FDA records drug Class II recall D-0559-2024, published June 26, 2024 and initiated May 30, 2024. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 3,552 bottles; Lot: Lot F201519, Expiry: November 2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Content Uniformity Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if CEFIXIME has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CEFIXIME
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide in the US
UPC
0368180423089
Lot
Lot F201519, Expiry: November 2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03 recalled?

Yes. FDA published recall D-0559-2024 on June 26, 2024. Reported hazard: Failed Content Uniformity Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CEFIXIME. UPC: 0368180423089.